Celyad Presents Clinical Update for CYAD-01 at 24th Congress of the European Hematology Association

Celyad Presents Clinical Update for CYAD-01 at 24th Congress of the European Hematology Association

Celyad to Present Update on allogeneic and autologous NKG2D-based CAR-T Candidates in Refractory mCRC at ESMO 21st World GI Congress

Celyad to Present Update on allogeneic and autologous NKG2D-based CAR-T Candidates in Refractory mCRC at ESMO 21st World GI Congress

Celyad’s 2019 R&D Day Highlights shRNA Platform and Pipeline of Next-generation NKG2D-based and Off-the-Shelf Non-gene Edited CAR-T Candidates

Celyad’s 2019 R&D Day Highlights shRNA Platform and Pipeline of Next-generation NKG2D-based and Off-the-Shelf Non-gene Edited CAR-T Candidates

Celyad successfully administers CYAD-01 in first patients in SHRINK and LINK trials

Celyad successfully administers CYAD-01 in first patients in SHRINK and LINK trials

Celyad announces initiation of the SHRINK trial

Celyad announces initiation of the SHRINK trial

Celyad publishes additional pre-clinical data in support of THINK trial

Celyad publishes additional pre-clinical data in support of THINK trial

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

Celyad obtains additional US patent for cancer treatment based on TCR-deficient allogeneic CAR-T cells

Celyad obtains additional US patent for cancer treatment based on TCR-deficient allogeneic CAR-T cells

Celyad initiates second dose escalation in THINK trial in first US patient

Celyad initiates second dose escalation in THINK trial in first US patient

Celyad issues a White Paper about CAR T NKR-2 current knowledge and differences with classical CAR-T technologies

Celyad issues a White Paper about CAR T NKR-2 current knowledge and differences with classical CAR-T technologies

USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells

USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells

Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA

Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA